Collste P, Nordlander R
Br J Clin Pharmacol. 1979 Mar;7(3):293-7. doi: 10.1111/j.1365-2125.1979.tb00935.x.
1 Plasma concentrations of quinidine were analyzed in 52 cardiac patients after different oral loading doses and during different maintenance dosage intervals using both conventional and sustained release preparations of quinidine. 2 The majority of patients reached therapeutic plasma concentrations in the order of 2--4 microgram/ml within 3 h after the loading dose of 600--800 mg of rapidly absorbed ordinary quinidine sulphate tablets and institution of maintenance therapy with sustained release tablets 1 h after the loading dose. 3 The dosage interval of 12 h during maintenance therapy with sustained release tablets gave as acceptable plasma drug fluctuations as an 8 h interval. 4 A large individual variation in plasma concentrations was noticed. Thus monitoring of therapy by plasma concentration analyses is desirable.
采用常规和缓释奎尼丁制剂,对52例心脏病患者在服用不同口服负荷剂量后以及不同维持剂量间隔期间的血浆奎尼丁浓度进行了分析。
大多数患者在服用600 - 800mg快速吸收的普通硫酸奎尼丁片负荷剂量后3小时内达到2 - 4微克/毫升的治疗血浆浓度,并在负荷剂量后1小时开始用缓释片进行维持治疗。
用缓释片维持治疗期间12小时的剂量间隔与8小时间隔产生的血浆药物波动相当。
注意到血浆浓度存在很大的个体差异。因此,通过血浆浓度分析监测治疗是可取的。